Svep.Wa
SVEP.WA operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
Business. SVEP.WA operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SVEP.WA operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
SVEP.WA has a debt-to-equity ratio of 0.68, indicating a moderate level of leverage relative to its equity base. The company's liquidity position is assessed as medium, with cash and equivalents amounting to 1.67 million PLN, which is significantly lower than its long-term debt of 84.65 million PLN. This suggests that the company may face challenges in meeting its long-term obligations without additional financing or operational improvements.
In terms of profitability, SVEP.WA reported revenue of 42.01 million PLN, but the company's total liabilities exceed its total equity, indicating a net debt position. The company's return on invested capital (ROIC) and other profitability metrics are not provided, making it difficult to assess its efficiency in generating returns relative to industry benchmarks.
The company's revenue is not segmented by product or geographic region in the provided data, so it is unclear whether SVEP.WA has significant concentration risks in any particular segment or market. Without detailed segment reporting, it is also difficult to evaluate the company's exposure to different therapeutic areas or geographic markets.
Looking ahead, SVEP.WA's growth trajectory is uncertain due to the lack of specific guidance on future revenue or earnings. The company's current revenue of 42.01 million PLN provides a baseline, but without additional data on historical growth or forward-looking projections, it is difficult to assess the company's potential for expansion.
The company's risk profile includes a medium liquidity risk, as its cash and equivalents are insufficient to cover its long-term debt. Additionally, the company's dilution risk is assessed as low, suggesting that there is little immediate threat to shareholder value from new share issuances. However, the company's net cash position is negative after accounting for total debt, which could limit its financial flexibility and increase its reliance on external financing.
Recent events and filings for SVEP.WA are not detailed in the provided data, so it is unclear whether the company has issued any new shares, taken on additional debt, or made any strategic acquisitions or partnerships that could impact its financial position.
- SVEP.WA has a moderate debt-to-equity ratio of 0.68, indicating a balanced capital structure.
- The company's liquidity position is medium, with cash and equivalents significantly lower than its long-term debt.
- SVEP.WA's profitability metrics are not provided, making it difficult to assess its efficiency in generating returns.
- The company's revenue is not segmented, so it is unclear whether it has significant concentration risks in any particular segment or market.
- SVEP.WA's growth trajectory is uncertain due to the lack of specific guidance on future revenue or earnings.
- The company's risk profile includes a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- SVEP.WA Market data — financials · 2026-05-29
Ownership & reference
Leadership
- Dariusz KucowiczMember of the Management Board
- Jaroslaw BlaszczakChairman of the Supervisory Board
- Piotr FicMember of the Management Board